News

The Data Monitoring Committee decided to stop enrollment following an independent recommendation that no new or recently enrolled patients continue treatment in the trial because of safety concerns

Trabedersen is a first-in-class gene silencing antisense compound designed to inhibit the tumour factor – transforming growth factor beta 2 (TGF-ß2) at its translational level. The efficacy and

The DeepSeq Solution is based on the proven RainStorm microdroplet-based single molecule PCR technology and is optimised for both fresh frozen and FFPE tissue. It delivers high specificity,

According to the lawsuit, FDA has knowingly allowed sodium thiopental, which has not been approved by the FDA, to be imported by state corrections agencies for use in

For the fourth quarter of 2010, the company posted an operating income of $367.4m, compared to $316.9m for the same period in 2009. For the full year ended

The company has successfully completed two Phase I trials of EGEN-001, in which the treatment resulted in good safety, biological activity and encouraging efficacy. EGEN-001 received Orphan Drug

Fera Pharma is launching Puralube in a 3.5g tube as well as a carton of 20 1g tubes. Fera Pharmaceuticals has launched its over-the-counter (OTC) dry eye treatment,

Shire claims that Vyvanse is the first and only once-daily prodrug stimulant approved to treat ADHD in adolescents and adults. The FDA’s approval of Vyvanse in adolescents and

Pilgrim’s Document Management solution will replace a paper-based system to better manage Megadyne’s increasing volume of documentation and related change controls by enabling the company to effectively create,